Human Reproduction, Vol. 14, No. 9, 2242-2244,
September 1999
© 1999 European Society of Human Reproduction and Embryology
High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze–thaw cycles
1 Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel, 2 Fertilitets Centrum, Carlanderska Sjukhuset, Göteborg, Sweden, 3 Academic Hospital, Free University Brussels, Brussels, Belgium, 4 Dijkzigt Academic Hospital, Rotterdam, The Netherlands, 5 Infertility IVF Centre `Geniki Cliniki', Thessaloniki, Greece and 6 NV Organon, Clinical Development Department, Oss, The Netherlands
The clinical application of gonadotrophin-releasing hormone (GnRH) antagonists instead of GnRH agonists, to prevent spontaneous premature luteinizing hormone surge during ovarian stimulation for assisted reproduction treatment has been advocated. A recent, double-blind, dose-finding study, including six dosages of the GnRH antagonist ganirelix, in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (FSH), has indicated that high doses of GnRH antagonist (1 or 2 mg once daily) are associated with a low implantation rate. This follow-up study reports on the pregnancy rate after replacement of cryopreserved embryos obtained in stimulation cycles of the above-mentioned trial. Ovarian stimulation was initiated on day 2 of the cycle, with daily injections of 150 IU recombinant FSH. Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) was administered once daily from stimulation day 6 onwards, up to and including the day of human chorionic gonadotrophin. Retrieved oocytes were fertilized by in-vitro fertilization (IVF) or intracytoplasmic sperm injection and a maximum of three fresh embryos was transferred. Excess embryos were frozen, and subsequently used in either natural or programmed cycles. Until June 1998, 11 ongoing pregnancies (12–16 weeks after embryo transfer) were achieved from 46 cycles in which embryos had been first frozen (23.9% per transfer). Six of these 11 patients had been treated with a high dose of ganirelix (1.0 or 2.0 mg) during the IVF cycles in which the embryos were obtained. In conclusion, our data suggest that high dosages of ganirelix do not adversely affect the potential of embryos to establish clinical pregnancy in freeze–thaw cycles.
Key words: ganirelix/GnRH antagonist/ovarian stimulation/pregnancy/recombinant human FSH
7 To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A.B. Klemmt, F. Liu, J. G. Carver, C. Jones, D. Brosi, J. Adamson, H. J. Mardon, and E. McVeigh Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro Hum. Reprod., September 1, 2009; 24(9): 2187 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hayden GnRH analogues: applications in assisted reproductive techniques Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S17 - S25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis Hum. Reprod. Update, November 1, 2006; 12(6): 651 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bodri, V. Vernaeve, J.J. Guillen, R. Vidal, F. Figueras, and O. Coll Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial Hum. Reprod., September 1, 2006; 21(9): 2246 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.M. Kolibianakis, J. Collins, B. Tarlatzis, E. Papanikolaou, and P. Devroey Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review Hum. Reprod. Update, January 1, 2006; 12(1): 3 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Simon, J. Oberye, J. Bellver, C. Vidal, E. Bosch, J.A. Horcajadas, C. Murphy, S. Adams, A. Riesewijk, B. Mannaerts, et al. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles Hum. Reprod., December 1, 2005; 20(12): 3318 - 3327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.E. Messinis, D. Loutradis, E. Domali, C.P. Kotsovassilis, L. Papastergiopoulou, A. Kallitsaris, P. Drakakis, K. Dafopoulos, and S. Milingos Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment Hum. Reprod., November 1, 2005; 20(11): 3192 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Diedrich, R. Frydman, P. Devroey, R. Felberbaum, A.V. Schally, T. Reissmann, and J. Engel Comment on the debate article: Embryo implantation: the Rubicon for GnRH antagonists Hum. Reprod., June 1, 2001; 16(6): 1305 - 1306. [Full Text] [PDF]
|
|
|
|
|
|
S. Kol Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation? Hum. Reprod., September 1, 2000; 15(9): 1881 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The European Orgalutran Study Group, G. Borm, and B. Mannaerts Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Hum. Reprod., July 1, 2000; 15(7): 1490 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Hernandez Embryo implantation and GnRH antagonists: Embryo implantation: the Rubicon for GnRH antagonists Hum. Reprod., June 1, 2000; 15(6): 1211 - 1216. [Abstract] [Full Text] [PDF]
|
|